Legend Biotech Reports 100% Response Rate And 83% Complete Remission Rate In Phase 1 Trial Of LB2501 In Vivo Dual-Targeting CAR-T Therapy For Relapsed/Refractory B-Cell Lymphoma

뉴스 본문을 불러오고 있어요.

Legend Biotech Reports 100% Response Rate And 83% Complete Remission Rate In Phase 1 Trial Of LB2501 In Vivo Dual-Targeting CAR-T Therapy For Relapsed/Refractory B-Cell Lymphoma | 웨이프 WAPE

Legend Biotech Reports 100% Response Rate And 83% Complete Remission Rate In Phase 1 Trial Of LB2501 In Vivo Dual-Targeting CAR-T Therapy For Relapsed/Refractory B-Cell Lymphoma

기사 요약

관련 종목

댓글 —